ATNM SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 7, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 8, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 30, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 14, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 8, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 9, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Actinium Pharmaceuticals Appoints Matt David, M.D. as Chief Financial Officer

Oct 15, 2026

8-K

Actinium Pharmaceuticals Announces Actimab-A Intellectual Property and Manufacturing Advances and Provides NYSE American Listing Update

Aug 14, 2026

8-K

Actinium Pharmaceuticals Submits Compliance Plan to NYSE American

Jun 18, 2026

8-K

Actinium Pharmaceuticals to Present ATNM-400 Program Update at SNMMI 2026 and Receives NYSE American Listing Standards Notice

May 29, 2026

8-K/A

Company to Conduct Annual Say-on-Pay Votes Following Shareholder Preference

Mar 26, 2026

8-K

Actinium Pharmaceuticals Announces CFO Resignation and Appointment of New Principal Financial Officer

Feb 13, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B3

UPDATED | ATM | Offering amount: $200,000,000.00 | Amount sold to date: $76,193,552.00

Jun 28, 2022

424B5

55,653,846 Shares Common Stock

Jun 18, 2020

424B5

Shares Common Stock

Jun 16, 2020

424B5

100,833,333 Shares Common Stock

Apr 22, 2020

424B5

Shares Common Stock

Apr 21, 2020

424B5

42,860,000 Shares Common Stock

Apr 18, 2019

Registrations

TYPE

HEADLINE

FILED AT

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Oct 9, 2026

S-8

Registration

Mar 29, 2024

S-3/A

SHELF | ATM | Offering amount: $500,000,000.00 EFFECTIVE

Feb 2, 2024

S-3

SHELF | ATM | Offering amount: $500,000,000.00 EFFECTIVE

Aug 11, 2023

S-8

Registration

Aug 19, 2022

S-3

Shares of our common stock having an aggregate offering price of up to $200,000,000.

Aug 7, 2020

Proxies

TYPE

HEADLINE

FILED AT

DEF 14A